FINWIRES · TerminalLIVE
FINWIRES

$DMRA

8 stories mentioning DMRAUpdated 39d ago

Every FINWIRES story that references DMRA, newest first.

What are analysts saying about DMRA?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on DMRA?

Wire

Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis

Damora Therapeutics (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.Price: $30.84, Change: $+0.82, Percent Change: +2.71%

$DMRA
Wire

Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating

Damora Therapeutics (DMRA) has an average rating of Buy and mean price target of $44.11, according to analysts polled by FactSet.Price: $29.32, Change: $-0.10, Percent Change: -0.34%

$DMRA
Wire

Damora Therapeutics Completes Redomestication to Cayman Islands

Damora Therapeutics (DMRA) said Friday it has completed its redomestication from the State of Delaware to the Cayman Islands, effective Thursday.The redomestication will not impact the company's business, management, obligations, assets or liabilities, according to a statement.Price: $31.60, Change: $+1.36, Percent Change: +4.50%

$DMRA
Research

HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target

Damora Therapeutics (DMRA) has an average rating of buy and mean price target of $43.38, according to analysts polled by FactSet.

$DMRA
Research

TD Cowen Initiates Damora Therapeutics at Buy

Damora Therapeutics (DMRA) has an average rating of buy and mean price target of 43.14, according to analysts polled by FactSet.

$DMRA
Research

Wedbush Initiates Damora Therapeutics at Outperform With $35 Price Target

Damora Therapeutics (DMRA) has an average rating of buy and mean price target of $43.14, according to analysts polled by FactSet.

$DMRA
Wire

Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says

Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin targeting therapies in myeloproliferative neoplasms, and may have the additional advantage of acharted regulatory path as a fast-follower over Incyte's (INCY) mid-stage candidate, RBC Capital said in a note emailed Friday.RBC said data from Incyte's (INCY) CALR antibody program have helped reduce uncertainty around the mechanism, strengthening confidence in its potential for treating conditions such as essential thrombocythemia and myelofibrosis.Damora's lead candidate DMR-001 may offer advantages such as extended half-life via YTE technology, higher potency, and a more consistent activity profile across mutation types, potentially addressing limitations of competing therapies, according to the report.The analyst sees DMR-001 reaching about $1.7 billion in peak U.S. potential, supported by improved dosing convenience and broader applicability, with a 60% probability of success in essential thrombocythemia and 35% in myelofibrosis.The firm said it expects the company's shares to appreciate to levels reflecting its long-term top-line potential.The report added that competitive clinical readouts could help de-risk the program, with early mid-2027 data viewed as a key potential catalyst for upside.RBC initiated the coverage on the company with an outperform rating on the stock with a price target of $40.Price: $24.02, Change: $-1.40, Percent Change: -5.51%

$DMRA$INCY
Research

RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target

Damora Therapeutics (DMRA) has an average rating of buy and mean price target of $45.17, according to analysts polled by FactSet.

$DMRA

Track with the FINWIRES app suite

FolioX
FolioX
Track DMRA in your portfolio
WheelAI
WheelAI
Analyze DMRA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on DMRA